Breaking News
October 20, 2018 - New approach to understanding cancers will accelerate development of better treatments
October 20, 2018 - LJI and UC San Diego awarded $ 4.5 million as part of NCI’s Cancer Moonshot initiative
October 20, 2018 - School-based HPV vaccination did not increase risky sexual behaviors among adolescent girls
October 20, 2018 - Eye discovery to pave way for more successful corneal transplants
October 20, 2018 - New analysis examines the importance of location in the opioid crisis
October 20, 2018 - Green filters increase reading speed for children with dyslexia
October 19, 2018 - Bariatric Sx Cuts Macrovascular Complications in Obesity, T2DM
October 19, 2018 - Better assessments for early age-related macular degeneration
October 19, 2018 - Visible and valued: Stanford Medicine’s first-ever LGBTQ+ Forum | News Center
October 19, 2018 - Understanding of metal-free enzymes used by bacteria could lead to new effective antibiotics
October 19, 2018 - Beckman Coulter Life Sciences announces new research-focused website
October 19, 2018 - Study finds link between refined soluble fibers, gut microbiota and liver cancer
October 19, 2018 - Social media reduces risk of depression among seniors with pain
October 19, 2018 - Newly developed synthetic DNA molecule may one day be used as ‘vaccine’ for prostate cancer
October 19, 2018 - Preoperative weight loss may not provide health benefits after surgery
October 19, 2018 - U.S. Birth Rates Continue to Drop as Age of New Moms Rises
October 19, 2018 - New technology can keep an eye on babies’ movements in the womb
October 19, 2018 - Juul e-cigarettes pose addiction risk for young users | News Center
October 19, 2018 - Gene sequencing reveals crucial molecular aspects of Trypanosoma brucei
October 19, 2018 - New DNA vaccine strategy protects mice against lethal challenge by multiple H3N2 viruses
October 19, 2018 - Study shows close link between cytokine interleukin-1ß and obesity-promoted colon cancer
October 19, 2018 - Muscle mass plays a critical role in health, shows research
October 19, 2018 - Study finds undiagnosed prediabetes in many infertile men
October 19, 2018 - The Current issue of “The view from here” is concerned with Nanotherapeutic strategies
October 19, 2018 - Delay in replacing the Pap smear with HPV screening is costing lives
October 19, 2018 - Physicians battle pediatric diseases of ear, nose, throat in Zimbabwe | News Center
October 19, 2018 - Researchers investigate why some cancers affect only young women
October 19, 2018 - Drugmakers funnel millions to lawmakers; a few dozen get $100,000-plus
October 19, 2018 - Unselfish people tend to have more children and receive higher salaries
October 19, 2018 - New findings reveal potential cellular players in tumor microenvironment
October 19, 2018 - Human brain cell transplant offers insights into neurological conditions
October 19, 2018 - Parental education associated with increased family health care spending
October 19, 2018 - New statistical method estimates long- and short-term risk of recurrence of breast cancer in US women
October 19, 2018 - Father’s exposure to nicotine may cause cognitive deficits in descendants
October 19, 2018 - Could we prevent Alzheimer’s disease by treating herpes?
October 19, 2018 - Nurse-led care can be more successful in managing gout
October 19, 2018 - Trump administration, pharma exchange verbal volleys on drug-price transparency
October 19, 2018 - Duke researchers find way to detect blood doping in athletes
October 19, 2018 - Many primary care doctors are still prescribing sedative drugs for older adults
October 19, 2018 - Finger length can predict sexuality in women say researchers
October 19, 2018 - Study finds differences in side-effects experienced by male and female OG cancer patients
October 19, 2018 - Dysfunction of single gene leads to miscarriages
October 19, 2018 - Few Seniors Who Self-Harm Referred for Mental Health Care
October 19, 2018 - Don’t sweat the sweet stuff
October 19, 2018 - URMC researchers discover new approach to deliver therapeutics to the brain
October 19, 2018 - Speech Pathology Australia raises awareness about Developmental Language Disorder
October 19, 2018 - Middlemen suppliers can increase drug prices and hospital bills, say Johns Hopkins researchers
October 19, 2018 - Survey finds high prevalence of HTLV-1 infection among teens and adults in Gabon
October 19, 2018 - Bliss funds research to find whether parental touch can help alleviate pain in premature infants
October 19, 2018 - Human neurons employ highly compartmentalized signaling, study shows
October 19, 2018 - Ultromics expands multiple clinical trials for coronary heart disease to the U.S.
October 19, 2018 - $11 million NIH grant for Clemson University helps launch new center for musculoskeletal research
October 19, 2018 - A new approach identified to control Zika virus, dengue fever
October 19, 2018 - Head Blows Without Concussion May Not Damage Brain, Study Claims
October 19, 2018 - US opioid use not declined, despite focus on abuse and awareness of risk
October 19, 2018 - Next-generation RNA sequencing technology sheds new light on human mitochondrial diseases
October 19, 2018 - UT Southwestern biochemist receives 2019 Breakthrough Prize in Life Sciences for innate immunity discovery
October 19, 2018 - The immune system also plays a key role in day-to-day function of healthy organs
October 19, 2018 - New tool may reveal how the brain structure impacts brain activity, human behavior
October 19, 2018 - Trump Administration announces ‘Winning on Reducing Food Waste’ initiative
October 19, 2018 - For-profit nursing home residents more likely to experience health issues caused by substandard care
October 19, 2018 - Incidence of stroke has risen steadily among marijuana users, show studies
October 19, 2018 - Conceptual framework proposed to examine role of exercise in multiple sclerosis
October 19, 2018 - Near infrared spectroscopy technique for accurate evaluation of chondral injuries
October 19, 2018 - Scientists receive $5.1 million grant to develop stem cell-based therapy for blinding retinal conditions
October 19, 2018 - Shorter physician encounters associated with antibiotic prescribing
October 19, 2018 - In the Spotlight: Enjoying research and exploring opportunities
October 19, 2018 - Physical activity lowers cardiovascular mortality risk in frail older adults
October 19, 2018 - New imaging tool helps visualize how sound-induced vibrations travel through the ear
October 19, 2018 - Key insights into the application, production of bioactive materials
October 19, 2018 - New urea sorbent could speed up the development of wearable artificial kidney
October 19, 2018 - Intensive care patients’ muscles less able to use fats for energy
October 19, 2018 - FDA Advisory Committee Recommends Approval of Dsuvia for the Treatment of Moderate-to-Severe Acute Pain
October 19, 2018 - 48,XXXY syndrome – Genetics Home Reference
October 19, 2018 - Physical exercise improves the elimination of toxic proteins from muscles
October 19, 2018 - How a new system improved wait times for Stanford kidney transplant patients
October 19, 2018 - Nutrition has bigger positive impact on bone mass and strength than exercise
October 19, 2018 - Study finds lack of progress in media representation of nurses over last 20 years
October 19, 2018 - Many people have trouble understanding differences between OCD and OCPD
October 19, 2018 - New family planning app found to be as effective as modern methods
No Efficacy Hit from Stopping Immunotherapy for AEs

No Efficacy Hit from Stopping Immunotherapy for AEs

image_pdfDownload PDFimage_print

Action Points

  • Efficacy outcomes were similar between patients who discontinued melanoma induction immunotherapy with nivolumab plus ipilimumab due to adverse events (AEs), and those who did not discontinue therapy.
  • Note that these pooled trial data suggest patients may continue to derive benefit even after treatment is stopped because of AEs, and response rate, depth of response, and overall survival do not seem to be diminished for these patients.

Patients who discontinued induction immunotherapy for advanced melanoma because of adverse events did just as well as those who continued treatment uninterrupted, a pooled analysis of randomized trials showed.

Patients who discontinued had an objective response rate of almost 60% compared with about 50% for those who finished induction therapy. Median progression-free survival (PFS) did not differ significantly between patients who discontinued and those who did not; median overall survival had yet to be reached in either group.

“Most patients who discontinued the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) did so before receiving all four doses of the combination,” Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues concluded in the Journal of Clinical Oncology.

“Efficacy of nivolumab plus ipilimumab seemed to be similar for those who did and did not discontinue because of adverse events. This suggests that patients may continue to derive benefit from combination therapy even after treatment is stopped because of adverse events.”

Despite the preliminary nature of the data, the findings raised “thought-provoking questions about the possible impact of early treatment cessation in the setting of toxicity on the durability of response,” two Australian oncologists wrote in an accompanying editorial.

“Several key messages ave arisen from this work,” said Matteo S. Carlino, MD, of the University of Sydney, and Shaneen Sandhu, MD, of Peter MacCallum Cancer Center and the University of Melbourne, in the editorial. “The response rate, depth of response, and overall survival do not seem to be diminished for patients who discontinue treatment as a result of immune-related adverse events at induction.

“In addition, the use of immunomodulatory agents to manage checkpoint inhibitor-related toxicities does not seem to hinder responses or durability of responses in the majority of patients who discontinue treatment because of immune-related adverse events at induction. The merits, liability, and optimal duration of ongoing anti-PD-1 therapy after discontinuing induction therapy because of immune-related adverse events will require prospective evaluation.”

The predictive utility of early-onset immune-related adverse events also requires further study, Carlino and Sandhu added.

Clinical trials of combined nivolumab-ipilimumab therapy for advanced melanoma showed that about 40% of patients discontinued induction therapy with the combination because of therapy-related adverse events. Most patients stopped before receiving the recommended four doses of therapy. The impact of early discontinuation on clinical outcomes remained unclear.

To investigate the impact of early discontinuation on outcomes, Postow and colleagues pooled data from randomized phase II and III trials involving a total of 409 patients with advanced melanoma treated with the combination of nivolumab and ipilimumab. Investigators compared treatment efficacy in 96 patients who discontinued treatment during the induction phase of therapy because of adverse events and in 233 patients who did not discontinue because of adverse events.

Investigators evaluated the safety of the combination in patients who discontinued treatment at any time because of adverse events versus those who who did not.

After a minimum follow-up for efficacy of 18 months, median PFS was 8.4 months (95% CI 5.8-16.7) in patients who discontinued induction therapy because of adverse events and 10.8 months (95% CI 5.9-23.0) in those who did not discontinue during induction therapy (P=0.97). The 18-month PFS was 38% in the patients who discontinued and 49% for those who did not. Median PFS had yet to be reached in either group (HR 0.79, 95% CI 0.54-1.17, P=0.2344).

The 18-month overall survival was 67% for patients who discontinued induction therapy because of adverse events and 62% for those who did not.

The objective response rate also did not differ significantly between patients who discontinued because of adverse events (58.3%) and patients who did not (50.2%).

The safety analysis showed that 156 of 407 (38%) patients discontinued treatment at any time because of adverse events, most of which were grade 3/4 severity. Colitis was the most common adverse event leading to discontinuation (10%), followed by elevated liver enzymes (4% to 5%). Colitis also was the most common serious adverse event leading to hospitalization (21% of all patients who discontinued treatment because of adverse events).

The most frequent grade 3/4 treatment-related adverse events associated with discontinuation at any time were gastrointestinal (especially diarrhea and colitis, 20% each). For patients who did not discontinue because of adverse events, the most common grade 3/4 adverse events were hepatic (10%).

Systemic corticosteroids were the most frequently used immunosuppressive therapy for management of adverse events, administered to 91% of patients who discontinued nivolumab-ipilimumab combination therapy because of adverse events and 55% of those who did not discontinue.

The study was supported by Bristol-Myers Squibb and the National Cancer Institute.

Postow disclosed relationships with Bristol-Myers Squibb, Marck, Amgen, Novartis, Array BioPharma, Infinity Pharmaceuticals, and RGenix. All of the coauthors disclosed relationships with one or more healthcare industry company.

Carlino disclosed relationships with Bristol-Myers Squibb, Merck, Amgen, Novartis, and Pierre Fabre. Sandhu disclosed relationships with Merck, Bristol-Myers Squibb, Amgen, and Janssen.


Tagged with:

About author

Related Articles